Trial Profile
A Phase I/II, Dose-escalation Study of Lipotecan Plus Radiotherapy in Locally Advanced Hepatocellular Carcinoma
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 03 Jul 2018
Price :
$35
*
At a glance
- Drugs TLC 388 (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Biomarker; Therapeutic Use
- Sponsors Taiwan Liposome Company
- 16 Apr 2013 Planned End Date changed from 1 Oct 2013 to 1 Oct 2015 as reported by ClinicalTrials.gov.
- 02 Sep 2011 New trial record